{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-25-000032","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.649386+00:00","generated_at":"2026-05-26T04:00:34.781445+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Chemed Q4 2024 revenue up 9.2% to $640M; adj. EPS $6.83; guides FY2025 adj. EPS $24.95-$25.45","bullets":["GAAP diluted EPS $6.02 (+2.0% YoY); adjusted diluted EPS $6.83 (+3.5% YoY).","VITAS net patient revenue $411M (+17.4% YoY); ADC 22,179 (+14.6%).","Roto-Rooter revenue $229M (-2.9% YoY); adjusted EBITDA margin 26.3% (-120 bps).","FY2025 guidance: VITAS revenue growth 10.5%-11.3%, Roto-Rooter revenue growth 2.4%-3.0%.","No debt; $178.4M cash; repurchased 388,235 shares for $212.8M at $548.13/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-25-000032","json":"https://secwatch.observer/filing/0001562762-25-000032.json","markdown":"https://secwatch.observer/filing/0001562762-25-000032.md","text":"https://secwatch.observer/filing/0001562762-25-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276225000032/0001562762-25-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276225000032/che-20250226x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:00:34.781445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}